Bone cancer pain

Annals of the New York Academy of Sciences

Volumn 1198, Issue , 2010, Pages 173-181

  Jimenez Andrade, Juan Miguel ^a   Mantyh, William G ^a   Bloom, Aaron P ^a   Ferng, Alice S ^a   Geffre, Christopher P ^a   Mantyh, Patrick W ^a,b,c  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c VA MEDICAL CENTER   (United States)

Author keywords

osteosarcoma; prostate; therapies

Indexed keywords

(5 TERT BUTYL 2,3 DIHYDRO 1H INDEN 1 YL) 3 (1H INDAZOL 4 YL)UREA; 4 CHLORO N (3 METHOXYPHENYL)CINNAMAMIDE; 4 [3 (TRIFLUOROMETHYL) 2 PYRIDINYL] N [5 (TRIFLUOROMETHYL) 2 PYRIDINYL] 1 PIPERAZINECARBOXAMIDE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM ION; DENOSUMAB; MORPHINE SULFATE; PYROPHOSPHORIC ACID DERIVATIVE; TANEZUMAB;

ACIDOSIS; ADVANCED CANCER; ANEMIA; ARTHRALGIA; BONE CANCER; BONE METASTASIS; BONE PAIN; BONE REMODELING; CANCER CELL; CANCER GROWTH; CANCER MORTALITY; CANCER PAIN; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFECT; FIBROBLAST; FRACTURE; HEALTH STATUS; HUMAN; INTROSPECTION; JAW OSTEONECROSIS; LUNG CANCER; MACROPHAGE; MORBIDITY; NEUROPATHIC PAIN; NEUTROPHIL; NONHUMAN; OSTEOARTHRITIS; OSTEOCLAST; PROSTATE CANCER; QUALITY OF LIFE; T LYMPHOCYTE; ANIMAL; BONE; BONE TUMOR; BREAST TUMOR; DISEASE MODEL; FEMALE; LUNG TUMOR; MALE; METASTASIS; MORTALITY; MOUSE; PAIN; PATHOLOGY; PATHOPHYSIOLOGY; PROSTATE TUMOR; REVIEW; SARCOMA; UNITED STATES;

ACIDOSIS; ANIMALS; BONE AND BONES; BONE NEOPLASMS; BREAST NEOPLASMS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MICE; NEOPLASM METASTASIS; OSTEOCLASTS; PAIN; PROSTATIC NEOPLASMS; SARCOMA; UNITED STATES;

EID: 77954597727     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.05429.x     Document Type: Conference Paper

References (34)

1. Coleman, R.E. 2006. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin. Cancer Res. 12 : 6243s 6249s.
2. Coleman, R.E. 1997. Skeletal complications of malignancy. Cancer 80 : 1588 1594.
3. Mercadante, S. 1997. Malignant bone pain: pathophysiology and treatment. Pain 69 : 1 18.
4. Zeppetella, G. 2009. Impact and management of breakthrough pain in cancer. Curr. Opin. Support Palliat. Care 3 : 1 6.
5. Arguello, F., R.B. Baggs C.N. Frantz. 1988. A murine model of experimental metastasis to bone and bone marrow. Cancer Res. 48 : 6876 6881.
6. Yoneda, T., A. Sasaki G.R. Mundy. 1994. Osteolytic bone metastasis in breast cancer. Breast Cancer Res. Treatment 32 : 73 84.
7. Honore, P. et al. 2000. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nat. Med. 6 : 521 528.
8. Schwei, M.J. et al. 1999. Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain. J. Neurosci. 19 : 10886 10897.
9. Sabino, M.A. et al. 2003. Different tumors in bone each give rise to a distinct pattern of skeletal destruction, bone cancer-related pain behaviors and neurochemical changes in the central nervous system. Int. J. Cancer 104 : 550 558.
10. Halvorson, K.G. et al. 2005. A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate tumor cells growing in bone. Cancer Res. 65 : 9426 9435.
11. Lipton, A. 2006. Future treatment of bone metastases. Clin. Cancer Res. 12 : 6305s 6308s.
12. Mantyh, P.W. 2006. Cancer pain and its impact on diagnosis, survival and quality of life. Nat. Rev. Neurosci. 7 : 797 809.
13. von Moos, R. et al. 2008. Metastatic bone pain: treatment options with an emphasis on bisphosphonates. Support Care Cancer 16 : 1105 1115.
14. Delaisse, J.M. G. Vaes. 1992. Mechanism of mineral solubilization and matrix degradation in osteoclastic bone resorption. In Biology and Physiology of the Osteoclast. B.R. Rifkin & C.V. Gay, Eds. : 289 314. CRC. Ann Arbor.
15. Drake, M.T., B.L. Clarke S. Khosla. 2008. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin. Proc. 83 : 1032 1045.
16. Halvorson, K.G. et al. 2006. Similarities and differences in tumor growth, skeletal remodeling and pain in an osteolytic and osteoblastic model of bone cancer. Clin. J. Pain 22 : 587 600.
17. Teitelbaum, S.L. 2007. Osteoclasts: what do they do and how do they do it? Am. J. Pathol. 170 : 427 435.
18. Julius, D. A.I. Basbaum. 2001. Molecular mechanisms of nociception. Nature 413 : 203 210.
19. Ghilardi, J.R. et al. 2005. Selective blockade of the capsaicin receptor TRPV1 attenuates bone cancer pain. J. Neurosci. 25 : 3126 3131.
20. Griffiths, J.R. 1991. Are cancer cells acidic? Br. J. Cancer 64 : 425 427.
21. Lipton, A. 2008. Emerging role of bisphosphonates in the clinic - antitumor activity and prevention of metastasis to bone. Cancer Treat Rev. 34 (Suppl 1 S25 S30.
22. Body, J.J. et al. 2006. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin. Cancer Res. 12 : 1221 1228.
23. http://clinicaltrials.gov. Accessed April 2009. NCT00556374, NCT00321620.
24. Lipton, A. S. Jun. 2008. RANKL inhibition in the treatment of bone metastases. Curr. Opin. Support Palliat. Care 2 : 197 203.
25. Niiyama, Y. et al. 2009. SB366791, a TRPV1 antagonist, potentiates analgesic effects of systemic morphine in a murine model of bone cancer pain. Br. J. Anaesth. 102 : 251 258.
26. Rubert Cynthia, H.R. M. Martin. 2000. Orthopedic management of skeletal metastases. In Tumor Bone Disease and Osteoporsis in Cancer Patients. J.-J. Body, Ed. : 305 356. Marcel Dekker. New York City.
27. Joyce, J.A. J.W. Pollard. 2009. Microenvironmental regulation of metastasis. Nat. Rev. Cancer 9 : 239 252.
28. Pezet, S. S.B. McMahon. 2006. Neurotrophins: mediators and modulators of pain. Annu. Rev. Neurosci. 29 : 507 538.
29. Sevcik, M.A. et al. 2005. Anti-NGF therapy profoundly reduces bone cancer pain and the accompanying increase in markers of peripheral and central sensitization. Pain 115 : 128 141.
30. Schnitzer, T.J. et al. 2008. Efficacy and safety of Tanezumab (PF04383119), an anti-nerve growth factor (NGF) antibody, for moderate to severe pain due to osteoarthritis (OA) of the knee: a randomized trial. In 12th World Congress of Pain: PT 214. Glasgow. Scotland, UK.
31. http://clinicaltrials.gov. Accessed April 2009. NCT00545129, NCT00830180.
32. Peters, C.M. et al. 2005. Tumor-induced injury of primary afferent sensory nerve fibers in bone cancer pain. Exp. Neurol. 193 : 85 100.
33. Obata, K. et al. 2003. Contribution of injured and uninjured dorsal root ganglion neurons to pain behavior and the changes in gene expression following chronic constriction injury of the sciatic nerve in rats. Pain 101 : 65 77.
34. http://clinicaltrials.gov. Accessed April 2009. NCT00381095.